Enterprise Therapeutics

18 articles with Enterprise Therapeutics

• 

  BioSpace Movers & Shakers, Feb. 11

  2/11/2022

  Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.

• Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001

  6/14/2021

  Enterprise Therapeutics Ltd, a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, announced it has successfully dosed the first subjects in a Phase 1 trial for its novel inhaled cystic fibrosis therapy, ETD001.

• Forbion Portfolio Company, Enterprise Therapeutics’ First-in-Class TMEM16A Potentiator Program for Treatment of Cystic Fibrosis and Other Respiratory Diseases Acquired by Roche

  10/7/2020

  Forbion, a leading European life sciences venture capital firm, announces that its portfolio company, Enterprise Therapeutics Ltd ’s novel TMEM16A potentiator portfolio has been fully acquired by Roche and will be developed by Genentech, a member of the Roche Group.

• Enterprise Therapeutics’ First-in-Class TMEM16A potentiator program for treatment of cystic fibrosis and other respiratory diseases acquired by Roche

  10/7/2020

  Enterprise’s novel TMEM16A potentiator portfolio includes ETD002, a first in class compound which is currently in Phase 1

• 

  Roche Carves Way into CF Space with Portfolio Acquisition

  10/7/2020

  This morning, the Swiss pharma giant acquired a portfolio of experimental cystic fibrosis therapies, including a candidate that has the potential to treat all patients with this disease.

• Enterprise Therapeutics Doses First Subjects in Phase 1 Trial for First-in-Class Cystic Fibrosis Therapy ETD002

  8/17/2020

  Enterprise Therapeutics Ltd, a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, announced it has successfully dosed the first subjects in a Phase 1 trial for its novel inhaled cystic fibrosis therapy, ETD002.

• 

  BioSpace Movers & Shakers, Feb. 14

  2/14/2020

  Biopharma and life sciences companies bolster their leadership teams and board with this week's Movers & Shakers.

• Enterprise Therapeutics appoints Dr David Morris MD as Chief Medical Officer

  2/10/2020

  Dr Morris will lead Enterprise’s therapeutics development strategy and drive the Company’s two lead respiratory programmes through the clinic

• Enterprise Therapeutics Publishes Paper on Novel Therapeutic Approach for Treatment of All Cystic Fibrosis Patients

  1/8/2020

  “TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis” published in American Journal of Respiratory and Critical Care Medicine

• 

  BioSpace Global Roundup, Oct. 17

  10/17/2019

  Companies from across the globe provide business and pipeline updates.

• Enterprise Therapeutics Awarded up to £5.7M ($7M) from Cystic Fibrosis Foundation to Support Clinical Development of Novel Chloride Channel Modulator

  10/15/2019

  Support for clinical development up to end of Phase 2 for ETD002, first-in-class TMEM16A potentiator for the treatment of all cystic fibrosis patients

• 

  BioSpace Movers and Shakers: March 29

  3/29/2019

  Biotech and pharma companies bring on new talent to strengthen leadership teams and boards.

• Enterprise Therapeutics strengthens leadership team, appoints Amit D. Munshi as Non-Executive Chairman

  3/25/2019

  Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced the appointment of Amit D. Munshi as Non-Executive Chairman of the Board of Directors.

• Enterprise Therapeutics Raises £29 Million ($41 Million USD) Funding

  4/12/2018

  Enterprise Therapeutics Ltd announced that it has closed an oversubscribed £29 million ($41 million USD) Series B round co-led by Versant Ventures and Novartis Venture Fund.

• Epidarex-backed Enterprise Therapeutics raises £29 million (USD$41 million) funding

  4/12/2018

  Enterprise Therapeutics Ltd announced that it has closed an oversubscribed £29 million ($41 million USD) Series B round co-led by Versant Ventures and Novartis Venture Fund. The syndicate also included new investor Forbion, founding investor Epidarex Capital and existing investor IP Group.

• Enterprise Therapeutics Receives Funding From Cystic Fibrosis Trust

  4/5/2017

• Enterprise Therapeutics Announces £4 Million ($5 Million USD) Fundraising

  11/10/2016

• Enterprise Therapeutics Appoints Dr John Ford as CEO

  10/17/2016